US FDA accepts application for psoriasis drug: Sun Pharma - Hindustan Times
close_game
close_game

US FDA accepts application for psoriasis drug: Sun Pharma

New Delhi | ByPress Trust of India
May 25, 2017 07:56 PM IST

The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency in March 2017.

Drug major Sun Pharmaceutical Industries on Wednesday said the US health regulator has accepted biologics licence application (BLA) for tildrakizumab for the treatment of psoriasis.

Sun Pharma says acceptance of the regulatory filing of for tildrakizumab by the US FDA marks a significant milestone.(HT photo)
Sun Pharma says acceptance of the regulatory filing of for tildrakizumab by the US FDA marks a significant milestone.(HT photo)

“The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis,” Sun Pharma said in a regulatory filing.

Hindustan Times - your fastest source for breaking news! Read now.

Sun Pharma CEO -North America Business Abhay Gandhi said: “The acceptance of the regulatory filing by the US FDA marks a significant milestone as we seek to advance for tildrakizumab as a potential new treatment option for people who continue to struggle everyday with the chronic nature of psoriasis”.

The company said that the BLA filing for tildrakizumab with the US FDA is based on two pivotal Phase III trials which included over 1,800 patients across more than 200 clinical trial sites, including some patients who have been treated with tildrakizumab for up to three-and-a-half years.

The BLA filing for tildrakizumab was submitted by Merck & Co., Inc., Kenilworth, NJ, USA, it added.

The BLA is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce, as per the US FDA.

Shares of Sun Pharma were trading 0.23% higher at Rs 613.95 on BSE.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away!- Login Now!
Stay informed on Business News along with Gold Rates Today, India News and other related updates on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, March 19, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On